

Editorial

Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture?

□□ *Commentary on Vesselle et al., p. 3255*

Wolfgang A. Weber, Johannes Czernin, and Michael E. Phelps3105

The Biology Behind

Multiple Cytokine and Growth Factor Serum Biomarkers Predict Therapeutic Response and Survival in Advanced-Stage Head and Neck Cancer Patients.

□□ *Commentary on Allen et al., p. 3182*

William L. Bigbee, Jennifer R. Grandis, and Jill M. Siegfried.....3107

Molecular Pathways

The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy.

Robert T. Abraham and James J. Gibbons3109

Human Cancer Biology

Interaction between Cancer Cells and Stromal Fibroblasts Is Required for Activation of the uPAR-uPA-MMP-2 Cascade in Pancreatic Cancer Metastasis. Yu He, Xiang-de Liu,

Zhi-yu Chen, Jin Zhu, Yan Xiong, Kun Li, Jia-hong Dong, and Xiaowu Li3115

Molecular Characterization of Inflammatory Genes in Sentinel and Nonsentinel Nodes in Melanoma. Hitoe Torisu-Itakura, Jonathan H. Lee, Randall P. Scheri, Young Huynh, Xing Ye,

Richard Essner, and Donald L. Morton3125

DNA Copy Number Gains at Loci of Growth Factors and Their Receptors in Salivary Gland Adenoid Cystic Carcinoma. Hedy Vékony, Bauke Ylstra, Saskia M. Wilting, Gerrit A. Meijer,

Mark A. van de Wiel, C. René Leemans, Isaïc van der Waal, and Elisabeth Bloemena3133

Insulin-Like Growth Factor-I Produced by Seminal Vesicles: Relationship to Intraepithelial Basal Cell Hyperplasia in the Prostate. Fernando U. Garcia, Katarzyna Urbanska, Lauren Koltowski,

Krzysztof Reiss, and Christian Sell3140

Identification and Characterization of Novel Spliced Variants of Neuregulin 4 in Prostate Cancer. Nandini V.L. Hayes, Edith Blackburn, Laura V. Smart, Mary M. Boyle, Graham A. Russell,

Teresa M. Frost, Byron J.T. Morgan, Anthony J. Baines, and William J. Gullick.....3147

Cross-Linking of Signal Transducer and Activator of Transcription 3—A Molecular Marker for the Photodynamic Reaction in Cells and Tumors. Barbara W. Henderson, Cecilia Daroqui,

Erin Tracy, Lurine A. Vaughan, Gregory M. Loewen, Michele T. Cooper, and Heinz Baumann.....3156

Identification of *NTN4*, *TRAI*, and *STC2* as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins. Selma Esseghir, Alan Kennedy, Pooja Seedhar,

Ashutosh Nerurkar, Richard Poulson, Jorge S. Reis-Filho, and Clare M. Isacke.....3164

Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia. Tasneem Motiwala, Sarmila Majumder, Huban Kutay, David Spencer Smith,

Donna S. Neuberg, David M. Lucas, John C. Byrd, Michael Grever, and Samson T. Jacob3174

Imaging, Diagnosis, Prognosis

Nuclear Factor- κ B-Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. Clint Allen, Sonia Duffy, Theodoros Teknos,

Mozaffarul Islam, Zhong Chen, Paul S. Albert, Gregory Wolf, and Carter Van Waes3182

Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome. Qiwei Yang, Colleen M. Kiernan, Yufeng Tian, Helen R. Salwen, Alexandre Chlenski, Babette A. Brumback, Wendy B. London, and Susan L. Cohn.....	3191
Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy. Maria Hägg Olofsson, Takayuki Ueno, Yang Pan, Ren Xu, Feng Cai, Heiko van der Kuip, Thomas E. Muerdter, Maike Sonnenberg, Walter E. Aulitzky, Stephan Schwarz, Elina Andersson, Maria C. Shoshan, Aleksandra Mandic Havelka, Masakazu Toi, and Stig Linder	3198
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. Christine Desmedt, Fanny Piette, Sherene Loi, Yixin Wang, Françoise Lallemand, Benjamin Haibe-Kains, Giuseppe Viale, Mauro Delorenzi, Yi Zhang, Mahasti Saghatchian d'Assignies, Jonas Bergh, Rosette Lidereau, Paul Ellis, Adrian L. Harris, Jan G.M. Klijn, John A. Foekens, Fatima Cardoso, Martine J. Piccart, Marc Buyse, and Christos Sotiriou on behalf of the TRANSBIG Consortium.....	3207
A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer. Marta Sanchez-Carbayo, Nicholas D. Socci, Thomas Kirchoff, Nadina Erill, Keneth Offit, Bernard H. Bochner, and Carlos Cordon-Cardo	3215
Distinction of Hereditary Nonpolyposis Colorectal Cancer and Sporadic Microsatellite-Unstable Colorectal Cancer through Quantification of MLH1 Methylation by Real-time PCR. Marcus Bettstetter, Stephan Dechant, Petra Ruemmele, Monika Grabowski, Gisela Keller, Elke Holinski-Feder, Arndt Hartmann, Ferdinand Hofstaedter, and Wolfgang Dietmaier	3221
KIF14 Messenger RNA Expression Is Independently Prognostic for Outcome in Lung Cancer. Timothy W. Corson, Chang Qi Zhu, Suzanne K. Lau, Frances A. Shepherd, Ming-Sound Tsao, and Brenda L. Gallie	3229
Association between the Estrogen Receptor α A908G Mutation and Outcomes in Invasive Breast Cancer. Matthew H. Herynk, Irma Parra, Yukun Cui, Amanda Beyer, Meng-Fen Wu, Susan G. Hilsenbeck, and Suzanne A.W. Fuqua	3235
Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival. Julia S. Johansen, Klaus Brasso, Peter Iversen, Børge Teisner, Patrick Garnero, Paul A. Price, and Ib Jarle Christensen	3244
Effect of Positive Bone Marrow EBV <i>In situ</i> Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. Jeeyun Lee, Cheolwon Suh, Jooryung Huh, Hyun Jung Jun, Kihyun Kim, Chulwon Jung, Keunchil Park, Yeon Hee Park, Young Hye Ko, and Won Seog Kim.....	3250
Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role. Hubert Vesselle, Joseph D. Freeman, Linda Wiens, Joshua Stern, Huang Q. Nguyen, Stephen E. Hawes, Philip Bastian, Alexander Salskov, Eric Vallières, and Douglas E. Wood.....	3255

Cancer Therapy: Clinical

Body Composition as an Independent Determinant of 5-Fluorouracil-Based Chemotherapy Toxicity. Carla M.M. Prado, Vickie E. Baracos, Linda J. McCargar, Marina Mourtzakis, Karen E. Mulder, Tony Reiman, Charles A. Butts, Andrew G. Scarfe, and Michael B. Sawyer	3264
UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan. Jean-François Côté, Sylvain Kirzin, Andrew Kramar, Jean-François Mosnier, Marie-Danièle Diebold, Isabelle Soubeyran, Anne-Sophie Thirouard, Janick Selves, Pierre Laurent-Puig, and Marc Ychou	3269
A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients. Isa E.L.M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Sandra A. Radema, Elaine M. Paul, Steve G. Mangum, Jos H. Beijnen, Emile E. Voest, and Jan H.M. Schellens	3276

A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. Andrew M. Scott, Niall Tebbutt, Fook-Thean Lee, Tina Cavicchiolo, Zhanqi Liu, Sanjeev Gill, Aurora M.T. Poon, Wendie Hopkins, Fiona E. Smyth, Carmel Murone, Duncan MacGregor, Anthony T. Papenfuss, Bridget Chappell, Timothy H. Saunder, Martin W. Brechbiel, Ian D. Davis, Roger Murphy, Geoffrey Chong, Eric W. Hoffman, and Lloyd J. Old	3286
Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. Alain C. Mita, Anthony J. Olszanski, Richard C. Walovitch, Raymond P. Perez, Kathleen MacKay, David P. Tuck, Cecilia Simmons, Susan Hammond, Monica M. Mita, Muralidhar Beeram, Anne J. Stone, Eric K. Rowinsky, and Lionel D. Lewis.....	3293
A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871. Lionel D. Lewis, Antonius A. Miller, Gary L. Rosner, Jonathan E. Dowell, Manuel Valdivieso, Mary V. Relling, Merrill J. Egorin, Robert R. Bies, Donna R. Hollis, Ellis G. Levine, Gregory A. Otterson, Frederick Millard, and Mark J. Ratain for the Cancer and Leukemia Group B	3302
Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer. Kim Margolin, Michael B. Atkins, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith II, Joseph I. Clark, Joseph Baar, Jeffrey Sosman, Jeffrey Weber, Chetan Lathia, Janice Brunetti, Frank Cihon, and Brian Schwartz	3312
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248. Steven P. Treon, Zachary R. Hunter, Jeffrey Matous, Robin M. Joyce, Brian Mannion, Ranjana Advani, David Cook, Joseph Songer, John Hill, Bruce R. Kaden, David Sharon, Ronald Steiss, Xavier Leleu, Andrew R. Branagan, and Ashraf Badros.....	3320

Cancer Therapy: Preclinical

A Novel Approach for Treatment of Unresectable Pancreatic Cancer: Design of Radioactive Stents and Trial Studies on Normal Pigs. Yan Liu, Jun-lou Liu, Zhen-zhai Cai, Zheng Lu, Yuan-hang Dong, Zhao-shen Li, Yan-fang Gong, and Xiao-hua Man.....	3326
Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2'-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. Ester Fonsatti, Hugues J.M. Nicolay, Luca Sigalotti, Luana Calabrò, Laura Pezzani, Francesca Colizzi, Maresa Altomonte, Massimo Guidoboni, Francesco M. Marincola, and Michele Maio	3333
Overexpression of <i>Clostridium perfringens</i> Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas. Alessandro D. Santin, Stefania Bellone, Eric R. Siegel, Jesse K. McKenney, Maria Thomas, Juan J. Roman, Alexander Burnett, Germana Tognon, Elisabetta Bandiera, and Sergio Pecorelli	3339
Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen. Cristina N. Boß, Frank Grünebach, Katharina Brauer, Maik Häntschel, Valbona Mirakaj, Toni Weinschenk, Stefan Stevanovic, Hans-Georg Rammensee, and Peter Brossart	3347
<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Christel Larbouret, Bruno Robert, Isabelle Navarro-Teulon, Simon Thèzenas, Maha-Zohra Ladjemi, Sébastien Morisseau, Emmanuelle Campigna, Frédéric Bibeau, Jean-Pierre Mach, André Pèlerin, and David Azria	3356
Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants. Teresa Guida, Suresh Anaganti, Livia Provitera, Richard Gedrich, Elizabeth Sullivan, Scott M. Wilhelm, Massimo Santoro, and Francesca Carlomagno.....	3363
Mifepristone Inhibits Ovarian Cancer Cell Growth <i>In vitro</i> and <i>In vivo</i>. Alicia A. Goyeneche, Rubén W. Carón, and Carlos M. Telleria.....	3370

Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma. Elias Drakos, Athanasios Thomaides, L. Jeffrey Medeiros, Jiang Li, Vasiliki Leventaki, Marina Konopleva, Michael Andreeff, and George Z. Rassidakis.....	3380
The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response. Amanda F. Baker, Terry Landowski, Robert Dorr, Wendy R. Tate, Jaime M.C. Gard, Breonna E. Tavenner, Tomislav Dragovich, Amy Coon, and Garth Powis.....	3388
Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization. Ruud P.M. Dings, Melissa Loren, Hanke Heun, Elizabeth McNeil, Arjan W. Griffioen, Kevin H. Mayo, and Robert J. Griffin.....	3395
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Ronald Koschny, Heidrun Holland, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Tom M. Ganten, Wolfgang Krupp, Manfred Bauer, Peter Ahnert, Jürgen Meixensberger, and Henning Walczak.....	3403
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells. Tianhong Li, Yi-He Ling, I. David Goldman, and Roman Perez-Soler.....	3413
Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway. Yvonne G. Lin, Ajaikumar B. Kunnumakkara, Asha Nair, William M. Merritt, Liz Y. Han, Guillermo N. Armaiz-Pena, Aparna A. Kamat, Whitney A. Spannuth, David M. Gershenson, Susan K. Lutgendorf, Bharat B. Aggarwal, and Anil K. Sood.....	3423

Letters to the Editor


The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor. Shinichi Toyooka, Hiroshi Date, Akiko Uchida, Katsuyuki Kiura, and Minoru Takata.....	3431
Reply to the Letter to the Editor from Toyooka et al. William Pao, Yixuan Gong, and Marissa Balak.....	3431
Therapeutic Role of Bisphosphonate and Radiation Combination in the Management of Myeloma Bone Disease. A. Ugur Ural and Ferit Avcu.....	3432

Correction

Article on High-Dose Interleukin-2 in Patients with Advanced Melanoma and Renal Cell Cancer.....	3433
---	------

About the Cover

The effects of curcumin on NF- κ B (*top row*), phospho-STAT3 (*middle row*), and COX-2 (*bottom row*) expression were examined in an orthotopic mouse model of ovarian carcinoma. Compared with controls (*left column*), treatment with oral curcumin (500 mg/kg) decreased expression of NF- κ B (p65), phospho-STAT3, and COX-2 as early as 24 hours after the last dose (*middle column*). Expression of these three factors returned to baseline levels by 72 hours after treatment (*right column*). The potent inhibition of these critical tumorigenic and angiogenic factors evidenced here support the development of curcumin-based therapeutic strategies for ovarian carcinoma. For further details, please see Lin *et al.* on page 3423 in this issue.



Clinical Cancer Research

13 (11)

Clin Cancer Res 2007;13:3105-3433.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/13/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/13/11>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.